QNTM
Quantum BioPharma Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$3.24
+9.83%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 250.8K | — | — | — | — |
| Gross Profit | (250.8K) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 1.6M | 2.8M | 6.1M | 3.9M | 6.9M |
| SG&A Expense | 10.1M | 12.0M | 9.3M | 13.2M | 16.0M |
| General & Admin Expense | 7.9M | 12.0M | 9.3M | 13.2M | 16.0M |
| Selling & Marketing Expense | 13.4K | — | — | — | — |
| Other Expenses | (10.0M) | 530.7K | 742.8K | 6.7M | 4.5M |
| Total Operating Expenses | 1.7M | 15.3M | 16.1M | 23.8M | 27.4M |
| Cost and Expenses | 1.9M | 15.3M | 16.1M | 23.8M | 27.4M |
| Operating Income (EBIT) | (1.9M) | (15.3M) | (16.1M) | (23.8M) | (27.4M) |
| Non-Operating | |||||
| Interest Income | 100.4K | 236.1K | 572.9K | 786.4K | 367.7K |
| Interest Expense | 382.7K | 618.6K | 47.6K | 299.00 | 48.8K |
| Net Interest Income | (282.3K) | (382.6K) | 525.3K | 786.1K | 318.9K |
| Other Non-Op Income/Expense | (23.1M) | (11.7M) | 1.2M | 5.6M | 725.9K |
| Non-Operating Income (excl Interest) | 22.3M | 11.0M | (1.3M) | (5.6M) | (774.8K) |
| EBT (Pre-Tax Income) | (25.0M) | (27.0M) | (14.9M) | (18.2M) | (26.7M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (24.9M) | (26.2M) | (14.2M) | (17.9M) | (23.6M) |
| Earnings from Cont. Ops | (25.0M) | (27.0M) | (14.9M) | (18.2M) | (26.7M) |
| Earnings from Discont. Ops | — | — | — | — | 3.1M |
| Bottom Line Net Income | (24.9M) | (26.2M) | (14.2M) | (17.9M) | (23.6M) |
| Per Share | |||||
| Basic EPS | ($5.65) | ($8.11) | ($12.49) | ($29.39) | ($39.62) |
| Diluted EPS | ($5.65) | ($8.11) | ($12.49) | ($29.39) | ($39.62) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 6.7M | 3.3M | 1.1M | 609056 | 595882 |
| Diluted Shares Outstanding | 6.7M | 3.3M | 1.1M | 609056 | 595882 |
| Profitability Metrics | |||||
| EBITDA | (23.7M) | (25.8M) | (14.4M) | (15.7M) | (22.1M) |
| D&A | 525.5K | 545.8K | 490.6K | 2.5M | 4.5M |
| EBIT | (24.2M) | (26.3M) | (14.9M) | (18.2M) | (26.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026